U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C27H39N3O
Molecular Weight 421.6181
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NEVANIMIBE

SMILES

CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC2(CCCC2)C3=CC=C(C=C3)N(C)C

InChI

InChIKey=PKKNCEXEVUFFFI-UHFFFAOYSA-N
InChI=1S/C27H39N3O/c1-19(2)23-10-9-11-24(20(3)4)25(23)29-26(31)28-18-27(16-7-8-17-27)21-12-14-22(15-13-21)30(5)6/h9-15,19-20H,7-8,16-18H2,1-6H3,(H2,28,29,31)

HIDE SMILES / InChI

Molecular Formula C27H39N3O
Molecular Weight 421.6181
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Nevanimibe (also known as PD-132301 and ATR101) is an acetyl-CoA C-acyltransferase (ACAT1) inhibitor. Millendo Therapeutics is currently advancing the development of nevanimibe for the treatment of two orphan adrenal diseases: classic congenital adrenal hyperplasia (CAH) and endogenous Cushing's syndrome (CS). Both of these diseases are associated with an overactive adrenal cortex causing excess steroid production. Millendo believes that nevanimibe represents an adrenal-specific approach that will address these diseases through the reduction of adrenal steroid production. Millendo is currently conducting Phase 2 clinical trial to assess the safety and efficacy of nevanimibe in subjects with endogenous Cushing’s syndrome and for the treatment of adult CAH.

Approval Year

PubMed

PubMed

TitleDatePubMed
Morphogenesis of a zone-specific adrenocortical cytotoxicity in guinea pigs administered PD 132301-2, an inhibitor of acyl-CoA:cholesterol acyltransferase.
1993
Subacute toxicity of a novel inhibitor of acyl-CoA: cholesterol acyltransferase in beagle dogs.
1993 Feb
Toxicologic effects of a novel acyl-CoA:cholesterol acyltransferase inhibitor in cynomolgus monkeys.
1994 Sep-Oct
Biochemical alterations in guinea pig adrenal cortex following administration of PD 132301-2, an inhibitor of acyl-CoA:cholesterol acyltransferase.
1995 Feb 17

Sample Use Guides

During the 12-week treatment period, all subjects will begin dosing with nevanimibe HCl (PD-132301) 1000 mg BID and be dose titrated to 1500 mg BID and then 2000 mg BID based upon the 17-OHP response that will be assessed every 4 weeks.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 02:14:00 GMT 2023
Edited
by admin
on Sat Dec 16 02:14:00 GMT 2023
Record UNII
VK9OS8R205
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NEVANIMIBE
USAN   INN  
Official Name English
PD 132301
Code English
ATR-101 FREE BASE
Code English
PD-132301
Code English
UREA, N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)-
Systematic Name English
NEVANIMIBE [USAN]
Common Name English
N-(2,6-BIS(PROPAN-2-YL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL) CYCLOPENTYL)METHYL)UREA
Systematic Name English
nevanimibe [INN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 497315
Created by admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
Code System Code Type Description
USAN
EF-118
Created by admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
PRIMARY
PUBCHEM
131679
Created by admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
PRIMARY
EPA CompTox
DTXSID10928286
Created by admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
PRIMARY
NCI_THESAURUS
C170216
Created by admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
PRIMARY
SMS_ID
100000177353
Created by admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
PRIMARY
INN
10892
Created by admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
PRIMARY
FDA UNII
VK9OS8R205
Created by admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
PRIMARY
CAS
133825-80-6
Created by admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
PRIMARY
Related Record Type Details
INHIBITOR -> TARGET
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY